- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus | 4 | Investing.com | ||
| Do | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| Do | Acrivon Therapeutics GAAP EPS of -$0.49 misses by $0.01 | 3 | Seeking Alpha | ||
| Do | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | 168 | GlobeNewswire (Europe) | Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation... ► Artikel lesen | |
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Acrivon Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| Di | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint ... | 5 | GlobeNewswire (USA) | ||
| 02.03. | Jefferies reiterates Acrivon Therapeutics stock rating on trial data | 17 | Investing.com | ||
| 27.02. | Acrivon präsentiert auf ESGO-Kongress neue Daten zu Krebsmedikament ACR-368 | 10 | Investing.com Deutsch | ||
| 27.02. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.01. | Acrivon to present ACR-368 endometrial cancer data at ESGO congress | 17 | Investing.com | ||
| 23.01. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress | 10 | GlobeNewswire (USA) | ||
| 09.01. | Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data | 11 | Investing.com | ||
| 08.01. | Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data | 4 | RTTNews | ||
| 08.01. | Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls | 11 | Benzinga.com | ||
| 08.01. | Acrivon reports 52% response rate in serous endometrial cancer trial | 3 | Investing.com | ||
| 08.01. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Acrivon to provide clinical updates on cancer drug candidates | 2 | Investing.com | ||
| 06.01. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast | 2 | GlobeNewswire (USA) | ||
| 17.12.25 | Acrivon to provide clinical data updates for cancer drugs in January | 1 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,30 | +0,26 % | Bioxyne vs. BioNTech: Australisches MDMA-Biotech hebt Prognose nach starkem Halbjahr an | ||
| MODERNA | 44,100 | -0,54 % | Pfizer vs Moderna: Which Pharma Stock Has More Upside? | ||
| PAION | 0,052 | -20,91 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| AMGEN | 298,60 | -0,85 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| NOVAVAX | 8,315 | -0,50 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 157,75 | -0,25 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| NANOREPRO | 1,435 | +0,35 % | NanoRepro: Neue Strategie rund um PHLAS | NanoRepro ist vielen Investoren noch als Anbieter von Corona-Schnelltests bekannt. Doch das Unternehmen hat sich strategisch neu positioniert. Im Podcast "NebenwerteWelt im Gespräch" erläutert CEO Lisa... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 1,400 | 0,00 % | H.C. Wainwright reiterates Inovio stock rating on FDA review | ||
| MAINZ BIOMED | 0,526 | -8,52 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| INFLARX | 0,811 | -0,67 % | InflaRx N.V.: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones | Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness... ► Artikel lesen |
Das Unternehmen ACRIVON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,050 (-2,92 %) liegt der Kurs bei 1,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.